Home
Screeners
All-In-One Screener
Dividend Income Portfolio
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
Good Companies
The Stalwarts
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances
Undervalued Predictable
Buffett-Munger
Low P/S
Low P/B
52w Low Predictable
Broadest Owned
Most Weighted
Gurus
Insiders
Market
Economic Data
Industry Overview
U.S. Treasury Yield Curve
Buffett Indicator
Global Market Valuations
Shiller P/E
Shiller P/E by Sectors
GF Value for SP500 Index
Buffett Assets Allocation
Articles
Tools
Tutorials
Support
Tutorial Session
Alnylam Pharmaceuticals Inc
$
127.26
-2.055 (-1.59%)
09:59 AM EST
P/E:
At Loss
P/B:
38.29
Market Cap:
$ 15.37B
Enterprise V:
$ 14.42B
Volume:
29.47K
Avg Vol (2M):
858.30K
Add to your portfolio
Volume:
29.47K
Market Cap $:
15.37B
PE Ratio:
At Loss
Avg Vol (2-Month):
858.30K
Enterprise Value $:
14.42B
PB Ratio:
38.29
Alerts RSS Website SEC Filings Stock Report Dataset Financial Download Tutorials
Tutorials
Add to your portfolio
Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Compare
Compare
Traded in other countries / regions
A1LN34.Brazil
•
DUL.Germany
•
ALNY.Mexico
•
0HD2.UK
•
ALNY.USA
Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.25 | |||||
| Equity-to-Asset | 0.12 | |||||
| Debt-to-Equity | 2.48 | |||||
| Debt-to-EBITDA | -1.53 | |||||
| Piotroski F-Score | 5/9 |
0
1
2
3
4
5
6
7
8
9
| ||||
| Altman Z-Score | 1.01 |
Distress
Grey
Safe
| ||||
| Beneish M-Score | -2.87 |
Manipulator
Not Manipulator
| ||||
| WACC vs ROIC |
WACC
ROIC
| |||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 112.3 | |||||
| 3-Year EBITDA Growth Rate | 11 | |||||
| 3-Year EPS without NRI Growth Rate | 1.7 | |||||
| 3-Year FCF Growth Rate | 4 | |||||
| 3-Year Book Growth Rate | -27.5 | |||||
| Total Revenue Growth Rate (Future 3Y To 5Y Est) | 44.13 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.36 | |||||
| 9-Day RSI | 41.7 | |||||
| 14-Day RSI | 39.9 | |||||
| 6-1 Month Momentum % | -3.12 | |||||
| 12-1 Month Momentum % | 23.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.27 | |||||
| Quick Ratio | 4.14 | |||||
| Cash Ratio | 3.7 | |||||
| Days Inventory | 212.42 | |||||
| Days Sales Outstanding | 62.5 | |||||
| Days Payable | 134.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.56 | |||||
| Operating Margin % | -76.04 | |||||
| Net Margin % | -101.47 | |||||
| ROE % | -126.66 | |||||
| ROA % | -25.78 | |||||
| ROIC % | -57.3 | |||||
| ROC (Joel Greenblatt) % | -102.74 | |||||
| ROCE % | -25.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 17.27 | |||||
| PB Ratio | 38.29 | |||||
| Price-to-Tangible-Book | 38.33 | |||||
| EV-to-EBIT | -19.11 | |||||
| EV-to-Forward-EBIT | -28.34 | |||||
| EV-to-EBITDA | -21.65 | |||||
| EV-to-Forward-EBITDA | -23.14 | |||||
| EV-to-Revenue | 16.06 | |||||
| EV-to-Forward-Revenue | 12.93 | |||||
| EV-to-FCF | -21.98 | |||||
| Price-to-Median-PS-Value | 0.2 | |||||
| Earnings Yield (Greenblatt) % | -5.23 |
Guru Trades
See DetailsTo
EMBED
SAVE
Insider Trades
See DetailsTo
EMBED
SAVE
Gurus Latest Trades with NAS:ALNY
No data
Annualized Return %
| Symbol | 1 Week | 1 Month | 3 Months | 6 Months | YTD | 1 Year | 3 Years | 5 Years | 10 Years |
|---|
Add to your portfolio
Total Annual Return %
| Symbol | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
Add to your portfolio
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 879.98 | ||
| EPS (TTM) ($) | -7.49 | ||
| Beta | 0.61 | ||
| Volatility % | 42.75 | ||
| 14-Day RSI | 39.9 | ||
| 14-Day ATR ($) | 7.154423 | ||
| 20-Day SMA ($) | 141.112 | ||
| 12-1 Month Momentum % | 23.14 | ||
| 52-Week Range ($) | 117.58 - 212 | ||
| Shares Outstanding (Mil) | 120.81 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alnylam Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Headlines
See More
Affiliate Program
Get WordPress Plugins
for easy affiliate links on Stock Tickers and Guru Names
GuruFocus Affiliate Program: Earn up to $400 per referral.
Detailed
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.